Veru (VERU) and Opiant (OPNT) Top Cantor Fitzgerald's List of Largest Short Interest Increases

In their most recent research note, Cantor Fitzgerald analysts review the most notable short interest changes in their biotech coverage universe:

The analyst comments: "In reviewing the most-updated short-interest data (4/26/2022) for companies in our sector, we see that the companies with the largest increases in short interest were Veru (NASDAQ: VERU) at +278.8% and Opiant Pharmaceuticals (NASDAQ: OPNT) at +67.8%. Merck (NASDAQ: MRK) also showed a meaningful increase in short interest at +14.4%. The companies with the most meaningful decreases in short interest were United Therapeutics (NASDAQ: UTHR) at -38.1% and Checkpoint Therapeutics (NASDAQ: CKPT) at -29.4%.

Additionally, we would like to highlight the companies in our coverage universe that have the highest short floats (percentage of shares in the market that are shorted in relation to all shares in the float); they include Heron (NASDAQ: HRTX) at 37.8% and Omeros (NASDAQ: OMER) at 18.5%."

By Vlad Schepkov

You May Also Be Interested In

• Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
• TechnipFMC (FTI) PT Raised to $30 at BTIG
• Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist Securities